Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Eli Lilly and Company

organization80% conf.·synced Oct 14, 2026

Pharmaceutical company with gene therapy licensing deal with REGENXBIO

60
sourced metrics
1289
relationships
20
stated objectives
3
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
1166.51USD
Oct 13, 2026reference only
Price 52 Week High
1280.34USD
Oct 13, 2026reference only
Market Cap
1098102429893USD
Oct 13, 2026reference only
Price 52 Week Low
799.57USD
Oct 13, 2026reference only
Stock Return Ytd
8.0%
Oct 13, 2026reference only
Shares Outstanding
941357065.0shares
Aug 3, 2026reference only
Net Income
7095000000.0USD
Jun 30, 2026reference only
Eps
7.94USD_per_share
Jun 30, 2026reference only
Revenue
22974000000.0USD
Jun 30, 2026reference only
Cash
8950000000.0USD
Jun 30, 2026reference only
Total Assets
142283000000.0USD
Jun 30, 2026reference only
Stockholders Equity
33879000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
3268000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
5333000000.0USD
Mar 31, 2026reference only

Stated objectives

Obtain U.S. regulatory approval for Inluriyo in combination with abemaciclib for ESR1-mutated MBC

source
stated

Advance LY4064809/STX-478 from Phase 1/2 to Phase 3 trial for PIK3CA-mutant HR+, HER2- advanced breast cancer

source
stated

Demonstrate overall survival benefit, progression-free survival, and time to chemotherapy improvements in EMBER-3 trial for ESR1-mutated breast cancer

source
stated

Show sustained IDFS/DRFS improvements and OS prolongation in monarchE trial across nodal status subgroups

source
stated

Translate biologic conviction into meaningful progress by addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K

source
stated

Demonstrate non-inferiority of pirtobrutinib versus ibrutinib on overall response rate in CLL/SLL patients

source
target: non-inferiority on ORR stated

Complete formal PFS analysis testing for superiority of pirtobrutinib

source
target: superiority on PFS stated

Verify and describe clinical benefit of Jaypirca in confirmatory trials to maintain accelerated approval status

source
target: clinical benefit verification stated

Demonstrate pirtobrutinib's potential role across treatment settings and B-cell malignancies through development program

source
stated

Receive regulatory approvals for pirtobrutinib in earlier disease settings to expand treatment options for patients

source
target: regulatory approval by 2026-01-01 00:00:00stated

Relationship graph · 1289 connections

Developed by
516
Competes with
198
Employs
86
Covered by
57
acquired by
54
regulates
45
headquartered in
45
located in
27
board member of
Dave Ricks

Via News coverage

Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI-Native Partner
June 19, 2026
Novo Nordisk Stock Surges 24.9% in 30 Days as AI Reshapes European Drug Discovery
May 27, 2026
Novo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Closes Internal Unit
May 16, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com